UBS Group
MACK

UBS Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

UBS Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,442
Closed -$184K – 10487
2024
Q1 		$184K Sell
12,442
-775
-6% -$10.9K ﹤0.01% 5911
2023
Q4 		$177K Buy
13,217
+7,369
+126% +$93.1K ﹤0.01% 5848
2023
Q3 		$72.1K Sell
5,848
-711
-11% -$8.61K ﹤0.01% 6060
2023
Q2 		$80.7K Buy
6,559
+3,431
+110% +$42.9K ﹤0.01% 6173
2023
Q1 		$38.4K Buy
3,128
+2,353
+304% +$27.7K ﹤0.01% 6626
2022
Q4 		$8.88K Sell
775
-4,421
-85% -$36.4K ﹤0.01% 8716
2022
Q3 		$19K Buy
5,196
+3,952
+318% +$18.2K ﹤0.01% 7500
2022
Q2 		$8K Sell
1,244
-1,059
-46% -$5.97K ﹤0.01% 8432
2022
Q1 		$15K Buy
2,303
+2,106
+1,069% +$11.8K ﹤0.01% 7907
2021
Q4 		$1K Hold
197
– – ﹤0.01% 10201
2021
Q3 		$1K Sell
197
-302
-61% -$1.57K ﹤0.01% 9448
2021
Q2 		$3K Sell
499
-1,194
-71% -$7.88K ﹤0.01% 8913
2021
Q1 		$10K Buy
1,693
+1,496
+759% +$10.7K ﹤0.01% 7980
2020
Q4 		$1K Hold
197
– – ﹤0.01% 8337
2020
Q3 		$1K Hold
197
– – ﹤0.01% 7920
2020
Q2 		$1K Sell
197
-2,353
-92% -$8.03K ﹤0.01% 7882
2020
Q1 		$5K Buy
2,550
+2,353
+1,194% +$6.88K ﹤0.01% 7358
2019
Q4 		$1K Sell
197
-2,558
-93% -$10.2K ﹤0.01% 8061
2019
Q3 		$13K Buy
2,755
+1,996
+263% +$9.97K ﹤0.01% 7035
2019
Q2 		$4K Sell
759
-1,922
-72% -$9.11K ﹤0.01% 7504
2019
Q1 		$14K Sell
2,681
-2,334
-47% -$10.7K ﹤0.01% 6623
2018
Q4 		$15K Buy
5,015
+2,207
+79% +$7.65K ﹤0.01% 7016
2018
Q3 		$12K Buy
2,808
+157
+6% +$662 ﹤0.01% 7098
2018
Q2 		$11K Buy
2,651
+1,994
+304% +$13.2K ﹤0.01% 7114
2018
Q1 		$4K Sell
657
-7,957
-92% -$65.8K ﹤0.01% 7384
2017
Q4 		$70K Sell
8,614
-605
-7% -$5.64K ﹤0.01% 5598
2017
Q3 		$105K Buy
9,219
+2,451
+36% +$25.8K ﹤0.01% 5291
2017
Q2 		$66K Sell
6,768
-12,560
-65% -$257K ﹤0.01% 5469
2017
Q1 		$468K Sell
19,328
-10,045
-34% -$251K ﹤0.01% 4086
2016
Q4 		$943K Buy
29,373
+17,047
+138% +$727K ﹤0.01% 3591
2016
Q3 		$615K Sell
12,326
-12,282
-50% -$510K ﹤0.01% 3773
2016
Q2 		$1.04M Buy
24,608
+6,967
+39% +$380K ﹤0.01% 3344
2016
Q1 		$1.16M Sell
17,641
-25,695
-59% -$1.34M ﹤0.01% 3122
2015
Q4 		$2.69M Buy
43,336
+18,696
+76% +$1.32M ﹤0.01% 2528
2015
Q3 		$1.65M Sell
24,640
-4
-0% -$326 ﹤0.01% 2914
2015
Q2 		$2.4M Sell
24,644
-2,681
-10% -$255K ﹤0.01% 2805
2015
Q1 		$2.55M Buy
27,325
+6,037
+28% +$514K ﹤0.01% 2707
2014
Q4 		$1.89M Buy
+21,288
New +$1.55M ﹤0.01% 2956

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS Group's MACK Position: Q2 2024 in Review

UBS Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 12,442 shares — an estimated $184K sold.

UBS Group first reported a position in MACK in Q4 2014 and held it in 38 quarters. The position peaked at $2.69M in Q4 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • UBS Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • UBS Group sold 12,442 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $184K.
  • UBS Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 38 quarters.
  • UBS Group's Merrimack Pharmaceuticals, Inc. position peaked at $2.69M in Q4 2015.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.